LONDON—After laying out the case for going it alone, AstraZeneca PLC executives have hit the road in Europe to win over investors, who could play a crucial role in determining whether Pfizer Inc.'s $106 billion unsolicited bid for the British drug maker goes ahead. . AstraZeneca laid out ambitious sales goals earlier this week after rejecting that bid of £50 ($84.78) a share from the U.S. company, saying it significantly undervalued the company. Pfizer, meanwhile, is weighing its options but so far has been mum on whether it...
  